Skip to main content


Log in

Association between adropin and coronary artery lesions in children with Kawasaki disease

  • Original Article
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript


Kawasaki disease (KD) is an acute systemic vasculitis in children. Coronary artery lesions (CALs) are the most serious complications in KD, but the pathogenesis is still unclear so far. Adropin, a new biopeptide, plays an important role in metabolism and cardiovascular function. The aim of this study was to explore the relationship between adropin and KD. 66 KD patients and 22 healthy controls (HCs) were included in the study. KD patients were divided into KD with coronary artery lesions (KD-CALs) group and KD without CALs (KD-NCALs) group. The levels of serum adropin were determined by enzyme-linked immunosorbent assay (ELISA). Compared with the HC group, adropin concentrations were significantly increased in the KD group (p < 0.05), and the KD-CAL group had higher levels of adropin than those in the KD-NCAL group (p < 0.05). Pct (Procalcitonin) and DD (D-dimer) were positively correlated with adropin in the KD group (p < 0.05). Moreover, adropin had positive correlations with CRP (C-reactive protein) and DD in the KD-NCAL group and positive correlations with Pct, PLR (platelet-to-lymphocyte ratio), and DD in the KD-CAL group (p < 0.05). The receiver operating characteristic (ROC) curve showed that the best threshold value of serum adropin level was more than 2.8 ng/mL, with 72.2% sensitivity and 71.4% specificity for predicting CALs in children with KD.

Conclusion: Adropin might be involved in the pathogenesis of KD and CALs and can be used as an auxiliary diagnostic biomarker of KD.

What is Known:

• CALs in KD were mainly caused by inflammation, immune imbalance, and vascular endothelial dysfunction, and adropin is involved in metabolic diseases and cardiovascular diseases.

What is New:

• In this study, we have found the relationship between adropin and KD, and serum adropin level can be used as an auxiliary diagnostic biomarker to predict CALs in KD

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

All datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability

Not applicable.



Protein Kinase B


Area under the curve


Activated partial thromboplastin time


Body mass index


C-reactive protein


Coronary artery lesions


Coronary artery aneurysm


Confidence interval




Endothelial NO synthase


Extracellular signal-regulated kinase 1/2


Enzyme-linked immunosorbent assay


Erythrocyte sedimentation rate




Healthy control


Kawasaki disease


Mean platelet volume


Percentage of leukomonocytes


Percentage of neutrophils


Neutrophil-to-lymphocyte ratio




Prothrombin time


Platelet counts


Phosphatidylinositol 3-kinase


Peroxisome proliferator-activated receptor γ


Platelet-to-lymphocyte ratio


Receiver operating characteristic


Statistical Package for Social Science


Standard deviations


Thrombin time


Vascular endothelial growth factor receptor-2


White blood cell counts


  1. Newburger JW (2000) Kawasaki disease. J Am Coll Cardiol 2:227–235

    CAS  Google Scholar 

  2. Del Principe D, Pietraforte D, Gambardella L et al (2017) Pathogenetic determinants in Kawasaki disease: the haematological point of view. J Cell Mol Med 21:632–639

    Article  PubMed  PubMed Central  Google Scholar 

  3. Laurito M, Stazi A, Delogu AB, Milo M, Battipaglia I, Scalone G, Infusino F, Villano A, Russo G, Iannotta R, Saracino A, Parrinello R, Figliozzi S, Sestito A, Romagnoli C, Lanza GA, Crea F (2014) Endothelial and platelet function in children with previous Kawasaki disease. Angiology 65:716–722

    Article  CAS  PubMed  Google Scholar 

  4. Takeshita S, Kanai T, Kawamura Y, Yoshida Y, Nonoyama S (2017) A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease. PLoS One 12:e0176957

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chen X, Zhao ZW, Li L et al (2015) Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease. Lipids Health Dis 14:1–9

    Article  Google Scholar 

  6. Bozlu G, Karpuz D, Hallioglu O, Unal S, Kuyucu N (2018) Relationship between mean platelet volume-to-lymphocyte ratio and coronary artery abnormalities in Kawasaki disease. Cardiol Young 28:832–836

    Article  PubMed  Google Scholar 

  7. Burns JC, Glode MP, Clarke S et al (1984) Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 105:206–211

    Article  CAS  PubMed  Google Scholar 

  8. Marczuk N, Cecerska-Heryć E, Jesionowska A, Dołęgowska B (2016) Adropin-physiological and pathophysiological role. Postepy Hig Med Dosw 70:981–988

    Article  Google Scholar 

  9. Yosaee S, Soltani S, Sekhavati E, Jazayeri S (2016) Adropin- a novel biomarker of heart disease: a systematic review article. Iran J Public Health 45:1568–1576

    PubMed  PubMed Central  Google Scholar 

  10. Niepolski L, Grzegorzewska AE (2016) Salusins and adropin: new peptides potentially involved in lipid metabolism and atherosclerosis. Adv Med Sci 61:282–287

    Article  PubMed  Google Scholar 

  11. Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, Sahin İ, Kocaman N, Citil C, Kendir Y (2013) Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 380:73–81

    Article  CAS  PubMed  Google Scholar 

  12. Briana DD, Boutsikou M, Boutsikou T, Marmarinos A, Gourgiotis D, Malamitsi-Puchner A (2017) Novel bioactive substances in human colostrum: could they play a role in postnatal adaptation? J Matern Fetal Neonatal Med 30:504–507

    Article  CAS  PubMed  Google Scholar 

  13. Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, Kokdasgil H (2016) Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy 117:100–105

    CAS  PubMed  Google Scholar 

  14. Yang F, Zhou L, Qian X, Wang D, He WJ, Tang ZW, Yin J, Huang QY (2017) Adropin is a key mediator of hypoxia induced anti-dipsogenic effects via TRPV4-CamKK-AMPK signaling in the circumventricular organs of rats. Front Mol Neurosci 10:105–105

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lin D, Yong J, Ni S, Ou W, Tan X (2019) Negative association between serum adropin and hypertensive disorders complicating pregnancy. Hypertens Pregnancy 38:237–244

    Article  CAS  PubMed  Google Scholar 

  16. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, Fan L (2014) Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 52:751–758

    CAS  PubMed  Google Scholar 

  17. Gulen B, Eken C, Kucukdagli OT, Serinken M, Kocyigit A, Kılıc E, Uyarel H (2016) Adropin levels and target organ damage secondary to high blood pressure in the ED. Am J Emerg Med 34:2061–2064

    Article  PubMed  Google Scholar 

  18. Han W, Zhang C, Wang H, Yang M, Guo Y, Li G, Zhang H, Wang C, Chen D, Geng C, Jiang P (2019) Alterations of irisin, adropin, preptin and BDNF concentrations in coronary heart disease patients comorbid with depression. Ann Transl Med 7:298–298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mccrindle BW, Rowley AH, Newburger JW et al (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135:e927–e999

    Article  PubMed  Google Scholar 

  20. Manlhiot C, Millar K, Golding F, McCrindle BW (2010) Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 31:242–249

    Article  PubMed  Google Scholar 

  21. Ronai C, Hamaoka-Okamoto A, Baker AL, de Ferranti SD, Colan SD, Newburger JW, Friedman KG (2016) Coronary artery aneurysm measurement and Z score variability in Kawasaki disease. J Am Soc Echocardiogr 29:150–157

    Article  PubMed  Google Scholar 

  22. Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H, Tan HL, Bandla HPR (2013) Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. J Pediatr 163:1122–1126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yu H, Zhao P, Wu M, Liu J, Yin W (2014) Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept 190-191:46–49

    Article  CAS  PubMed  Google Scholar 

  24. Özkan B, Örsçelik Ö, Yıldırım Yaroğlu H, Balcı Ş, Özcan MK, Çelik A, Özcan IT (2019) Association between serum adropin levels and isolated coronary artery ectasia in patients with stable angina pectoris. Anatol J Cardiol 22:250–255

    PubMed  PubMed Central  Google Scholar 

  25. Fan Z, Zhang Y, Zou F, Xu T, Pan P, Hu C, Su X (2020) Serum adropin level is associated with endothelial dysfunction in patients with obstructive sleep apnea and hypopnea syndrome. Sleep Breath.

  26. Gundogdu G, Gundogdu K (2018) A novel biomarker in patients with knee osteoarthritis: adropin. Clin Rheumatol 37:2179–2186

    Article  PubMed  Google Scholar 

  27. Celikhisar H, Ilkhan GD (2020) Alterations in serum adropin, adiponectin, and proinflammatory cytokine levels in OSAS. Can Respir J 2020:2571283–2571287.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Eser Karlidag G, Arslan Solmaz O (2020) Are adropin, apelin, elabela, asprosin and betatrophin biomarkers for chronic hepatitis and staging of fibrosis? Biotech Histochem 95:152–159

    Article  CAS  PubMed  Google Scholar 

  29. Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Çakmak T, Eren MN (2014) Elevated adropin: a candidate diagnostic marker for myocardial infarction in conjunction with troponin-I. Peptides 58:91–97

    Article  CAS  PubMed  Google Scholar 

  30. Palizban AA, Yazdani AH, Jahanbani-Ardakani H (2019) Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case-control study from Isfahan, Iran. Arch Physiol Biochem 9:1–4

    Article  Google Scholar 

  31. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M, Ferrante AW Jr, Mynatt RL, Burris TP, Dong JZ, Halem HA, Culler MD, Heisler LK, Stephens JM, Butler AA (2008) Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8:468–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M (2020) Adropin as a fat-burning hormone with multiple functions-review of a decade of research. Molecules 25:549

    Article  CAS  PubMed Central  Google Scholar 

  33. Yang C, Demars KM, Hawkins KE, Candelario-Jalil E (2016) Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions. Peptides 81:29–37

    Article  CAS  PubMed  Google Scholar 

  34. Zhang S, Chen Q, Lin X, Chen M, Liu QA (2020) Review of adropin as the medium of dialogue between energy regulation and immune regulation. Oxidative Med Cell Longev 4:3947806

    Google Scholar 

  35. Dominguez SR, Martin B, Heizer H, Jone PN, Tong S, Davidson J, Anderson MS, Glodé MP (2016) Procalcitonin (PCT) and Kawasaki disease: does PCT correlate with IVIG-resistant disease, admission to the intensive care unit, or development of coronary artery lesions. J Pediatric Infect Dis Soc 5:297–302

    Article  PubMed  Google Scholar 

  36. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, al-Omran M, Teoh H, Verma S (2010) Adropin is a novel regulator of endothelial function. Circulation 122:S185–S192

    Article  CAS  PubMed  Google Scholar 

Download references


This research was supported by the National Natural Science Foundation of China (81270412).

Author information

Authors and Affiliations



Maoling Yang: conceptualization, writing—original manuscript, investigation, writing—review and editing, software, and formal analysis. Qiongfei Pei: conceptualization and methodology. Jing Zhang: visualization and investigation. Haobo Weng: writing—reviewing and editing. Fengchuan Jing: writing—reviewing and editing. Qijian Yi: supervision, conceptualization, and writing—review and editing.

Corresponding author

Correspondence to Qijian Yi.

Ethics declarations

Ethics approval and consent to participate

Informed consent was obtained from the legal guardian of each patient. This research was approved by the ethics committee of Children’s Hospital of Chongqing Medical University. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.

Consent for publication

Written informed consent for publication was obtained from all participants.

Conflict of interest

All authors declare no conflict of interest.

Additional information

Communicated by Peter de Winter

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, M., Pei, Q., Zhang, J. et al. Association between adropin and coronary artery lesions in children with Kawasaki disease. Eur J Pediatr 180, 2253–2259 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: